Should You Buy Elevance Health, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Elevance Health, Inc. (ELV) is rated as a strong fundamental performer with a QOC score of 8.4/10. Trading at $417.54, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 2 of 6 CirclFi valuation models project upside for Elevance Health, Inc. (ELV) at $417.54 — the model consensus leans bearish, with a Quality Score of 8.4/10 and Value-Trap risk of 8/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Elevance Health, Inc. (ELV) in 2026?
What Is the Bull Case vs the Bear Case for Elevance Health, Inc. (ELV)?
| Bull case — $919.34 target (+120.2%) | Bear case — $276.11 target (-33.9%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Elevance Health, Inc.'s rating of 8.4/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $276.11 (-33.9%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $919.34 (+120.2%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +154.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Elevance Health, Inc.'s revenue and margin trajectory in the Healthcare Plans space. | Industry headwind: generic/biosimilar competition represents a meaningful risk for Elevance Health, Inc. and its Healthcare Plans peers. |
| The company's $90.6B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does ELV Compare to Its Healthcare Plans Peers?
Valuation data pages: PFHO · UNH · PGNY · CI · MRAI · MOH · CNC · CLOV
Which Other Stocks Score Like ELV on Quality?
Closest companies to ELV’s Quality of Company score of 8.4/10, across all industries.
- PSN — Parsons Corporation (QOC 8.4) · analysis
- IRS — IRSA Inversiones y Representaciones Sociedad Anónima (QOC 8.4) · analysis
- HAFC — Hanmi Financial Corporation (QOC 8.4) · analysis
- WMB — The Williams Companies, Inc. (QOC 8.4) · analysis
- FRHC — Freedom Holdings Corp. (QOC 8.4) · analysis
- AMPY — Amplify Energy Corp. (QOC 8.4) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Elevance Health, Inc. (ELV) Worth Buying in 2026?
Caution dominates our read on Elevance Health, Inc. at $417.54. 4 of 6 models see limited upside or outright downside, with the median fair value at $350.49 (-16.1%). Quality at 8.4/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Elevance Health, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ELV Stock?
Should I buy ELV stock right now?
Based on CirclFi's multi-model analysis, 2 of 6 models see upside for ELV at $417.54. The models are divided, which means the investment case depends heavily on your assumptions about Elevance Health, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Elevance Health, Inc.?
Key risks include: limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (233% spread), signaling high uncertainty; general market and sector-specific risks affecting Healthcare Plans companies. Always diversify and consult a financial advisor.
How does ELV compare to its competitors?
Among Healthcare Plans peers, ELV holds a Quality Score of 8.4/10. Comparable companies include PFHO (QOC 8.5), UNH (QOC 8.0), PGNY (QOC 8.6). The relative ranking helps investors identify whether ELV offers better fundamental quality than alternatives in the same sector.
Is ELV a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ELV's Quality Score of 8.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy ELV at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $276.11 to $919.34. At $417.54, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ELV.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad